Integra LifeSciences (NASDAQ:IART) Releases Q1 Earnings Guidance

Integra LifeSciences (NASDAQ:IART - Get Free Report) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.40 to $0.45 for the period, compared to the consensus estimate of $0.54. The company issued revenue guidance of $375 million to $385 million, compared to the consensus revenue estimate of $400.11 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Analyst Ratings Changes

Several research analysts have weighed in on IART shares. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price on the stock. Citigroup upped their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Integra LifeSciences has a consensus rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Price Performance

Shares of IART traded up $0.15 during mid-day trading on Friday, reaching $23.21. 698,610 shares of the company's stock were exchanged, compared to its average volume of 618,446. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The company has a 50-day simple moving average of $23.77 and a two-hundred day simple moving average of $21.85. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -257.86, a PEG ratio of 0.73 and a beta of 1.17. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $40.92.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm's revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $0.89 EPS. On average, sell-side analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.10% of the stock is currently owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.